NeuroPace Inc
About NeuroPace Inc
NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $100.0M
- Net income
- -$21.5M
- Total assets
- $105.6M
- Market cap
- $536.6M
- Gross margin
- 77.2%
- Operating margin
- -16.3%
- Net margin
- -21.5%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $100.0M
- Cost of revenue
- $22.8M
- Gross profit
- $77.2M
- Operating expenses
- $93.6M
- Operating income
- -$16.3M
- Income tax
- $0
- Net income
- -$21.5M
- EPS (basic)
- $-0.66
- EPS (diluted)
- $-0.66
Balance sheet
- Total assets
- $105.6M
- Current assets
- $94.1M
- Total liabilities
- $86.5M
- Current liabilities
- $17.8M
- Shareholders’ equity
- $19.0M
Cash flow
- Operating cash flow
- -$11.0M
- Investing cash flow
- -$332.0K
- Financing cash flow
- $19.6M
- Net cash flow
- $8.3M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $536.6M
- EPS (diluted)
- $-0.66
- Shares outstanding
- 34.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 22, 2021
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $21.5M in FY2025.
- Revenue grew 121% from FY2021 to FY2025.
- Gross margin of 77.2%, net margin -21.5%.
- Trading 19% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review NeuroPace Inc.
Write a review
News about NeuroPace Inc
News & sentiment via Polygon.io
